Lineage Cell Therapeutics prices $30M registered direct offering at $0.76/unit with warrants

Lineage Cell Therapeutics, Inc.

Combined purchase price of $0.76 per share and warrant; $24M from institutional investors, $6M from Broadwood affiliate.
Warrants exercisable at $0.91 for up to ~39.5M shares; expire 3 years from exercise date or 90 days post OpRegen milestone.
Broadwood portion requires shareholder approval under NYSE American rules; closing contingent on satisfaction of conditions.
Net proceeds to fund working capital, R&D, and capital expenditures; potential additional $36M if warrants exercised.
H.C. Wainwright serves as exclusive placement agent with 7% cash fee and 5% warrant coverage at $0.95 exercise price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.